Anticancer Bioscience Presenting at Biotech Showcase™ Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time

Chengdu, China, 12 January 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it is participating in Biotech Showcase™ Digital 2021, for the first time, providing an on-demand company presentation.

Thaddeus Allen PhD, VP, translational medicine, USA Business Development presents on behalf of ACB this year delivered digitally. He is attending alongside Jing Zhang PhD, VP, high throughput and high content screening.

ACB’s presentation showcases its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies.

An international private company, ACB is commercialising discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. The Company is using its unique small molecule and natural product libraries and its discovery platforms in cancer biology to discover novel mechanisms to induce cancer cell death, without harming healthy cells. The Company has five distinct synthetic lethality programs in drug development.

“Our goal at Biotech Showcase is to meet potential academic, biotech, CRO, pharma and financing partners to explore opportunities to support our ambition and accelerate our programs. We are impressed with the PartneringOne networking platform and are pleased to have secured some interesting meetings” said Dr Allen.

This year registered attendees to Biotech Showcase can access recorded company presentations via 24×7 on-demand access allowing attendees to view presentations at their convenience, avoiding conflicts with busy meeting schedules during the main event week, 11-15 January 2021 https://informaconnect.com/biotech-showcase/

Follow Anticancer Bioscience on LinkedIn and Twitter

About Anticancer Bioscience – https://www.anticancerbio.com/ 
Anticancer Bioscience (ACB) is an international private company, commercialising discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. Pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. It has raised USD20m and employees ~50 employees in Chengdu, China, Hyderabad, India, San Francisco, USA, and St Andrews, UK. ACB is based on over 20 years of collaborative research between founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop.

About Biotech Showcase 
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.